Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-8 long-term extension of inclisiran in high cardiovascular risk patients with elevated LDL-C
NL-OMON55497Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Primary endpoints: Proportion of subjects attaining global lipid targets at end of study and Safety and tolerability of long-term inclisiran. Started Jul 2019; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON55497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55497.